Table 2.

Myocardial Matrix Biomarker Profiles in Referent Control Subjects, Subjects with Left Ventricular Hypertrophy, and Subjects with Diastolic Heart Failure

	Patient Grouping			F (χ²)	p-Value
	Referent Control	LVH	DHF
MMP-1, ng/mL	0.78 ± 0.06	0.89 ± 0.07	0.94 ± 0.17	1.1	0.325
MMP-2, ng/mL	339.7 ± 9.3	326.4 ± 11.8	421.4 ± 21.6^*^†	9.6	<0.001
MMP-3, ng/mL	10.08 ± 0.39	9.33 ± 0.42	11.47 ± 0.74^†	3.0	0.049
MMP-7, ng/mL	1.65 ± 0.08	1.84 ± 0.10	2.14 ± 0.18^*	4.2	0.016
MMP-8, ng/mL	2.63 ± 0.22	3.29 ± 0.32	1.79 ± 0.18^†	4.4	0.014
MMP-9, ng/mL	95.0 ± 3.8	126.7 ± 7.2^*	123.8 ± 8.6^*	10.7	<0.001
TIMP-1, ng/mL	72.2 ± 1.4	82.5 ± 2.1^*	90.3 ± 3.4^*	18.5	<0.001
TIMP-2, ng/mL	78.6 ± 0.9	83.6 ± 1.1^*	85.3 ± 1.6^*	8.9	<0.001
TIMP-3, ng/mL	7.5 ± 0.5	9.2 ± 0.8	6.6 ± 0.9	2.8	0.063
TIMP-4, ng/mL	1.47 ± 0.04	1.46 ± 0.05	1.85 ± 0.09^*^†	8.9	<0.001
PINP, ng/mL	37.1 ± 1.3	34.5 ± 1.9	39.4 ± 4.0	1.1	0.327
PIIINP, ng/mL	7.2 ± 0.1	7.6 ± 0.2	9.1 ± 0.4^*^†	18.4	<0.001
CITP, ng/mL	3.01 ± 0.12	3.56 ± 0.17	3.93 ± 0.42^*	5.0	0.007
CTP-1, ng/mL10⁻³	51.1 ± 6.9	43.3 ± 6.8	22.8 ± 5.7	2.4	0.096
sRAGE, ng/mL	3.46 ± 0.17	3.15 ± 0.25	2.97 ± 0.27	1.2	0.315
Osteopontin, ng/mL	76.2 ± 1.9	86.5 ± 4.7^*	92.6 ± 5.5^*	5.1	0.007
NT-proBNP, pg/m	87.4 ± 6.4	109.4 ± 12.4	214.2 ± 33.6^*^†	17.7	<0.001
Sample Size, n	241	144	61

Abbreviations: The table presents means ± standard errors. ANOVA F-tests and p-values are reported for log₁₀ biomarker values and post hoc pairwise statistical comparisons were performed.

LVH = patients with left ventricular hypertrophy but no heart failure, DHF = patients with left ventricular hypertrophy and diastolic heart failure, MMP = matrix metalloproteinase, TIMP = tissue inhibitor of MMP, NT-proBNP = n-terminal propeptides of brain naturetic peptide, sRAGE = soluble receptor for advanced glycation endproduct, PINP = n-terminal collagen I propeptide, PIIINP = n-terminal collagen III propeptide, CITP = collagen I telopeptide, CTP = Cardiotropin-1.

= p<0.05 compared to Referent Control

^†

= p<0.05 compared to LVH.